Phenylketonuria — Research Summary
Printed from RareWays (rareways.com.au) on 10 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
A phenylketonuria mouse model exhibits EEG spike-wave discharges: Effects of sleep deprivation and low-Phe diet.
Cao Junfei et al. — Neurobiology of disease (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42242585/
- 2.
Associations between prenatal exposure to indoor air pollution and ambient particulate matter with infant growth.
Lyu Jinlang et al. — Journal of environmental sciences (China) (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42336570/
- 3.
Bioinformatics analysis of proteins in the complement and coagulation cascades in colon cancer: Discovering the potential biomarker SERPINA1.
Lian Da et al. — Oncology letters (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42375173/
- 4.
Care of patients with Phenylketonuria (PKU) in Germany - a claims data analysis from 2013 to 2023.
Boehnke Axel et al. — Orphanet journal of rare diseases (2 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42393732/
- 5.
Re: Pegvaliase Treatment for Adolescents With Phenylketonuria: A Multi-Site Study.
Hall Patricia L et al. — JIMD reports (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42299448/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study of JNT-517 in Participants With Phenylketonuria (PKU)
Recruiting — Phase 3 — Otsuka Pharmaceutical Development & Commercialization, Inc.
https://clinicaltrials.gov/study/NCT06971731
- 2.
A Long-Term Study of JNT-517 in Participants With Phenylketonuria
Recruiting — Phase 3 — Otsuka Pharmaceutical Development & Commercialization, Inc.
https://clinicaltrials.gov/study/NCT06628128
- 3.
A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
Recruiting — Phase 3 — PTC Therapeutics
https://clinicaltrials.gov/study/NCT06302348
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Phenylketonuria
Phenylketonuria is a genetic condition where the body cannot properly break down an amino acid called phenylalanine. Without management, it can cause brain damage. It is detected at birth through newborn screening, and a specialised low-phenylalanine diet is the main treatment.
Most Recent Research
Phenylketonuria (PKU) is an inherited metabolic disorder characterized by phenylalanine hydroxylase deficiency and elevated phenylalanine (Phe) levels in blood and brain, causing neurotoxicity and brain dysfunction. Elevated Phe levels may alter brain activity, as poor dietary control is linked to abnormal EEGs. However, knowledge on these electrophysiological characteristics remains limited. The current study applied electroencephalogram (EEG) recordings of brain activity in PAHenu2 mice, which have elevated Phe levels resembling untreated PKU patients. EEG recordings revealed frequent spontaneous spike wave discharges (referred to as SWDs) that predominantly occurred during wakefulness and rapid-eye-movement (REM) sleep and were accompanied by reduced muscle tone. Furthermore, SWD incidence was exacerbated by sleep deprivation and normalized during recovery sleep. While the overall amount of sleep was unchanged, PKU mice exhibited more fragmented sleep and mildly altered EEG slow-wave activity rebound following sleep deprivation. Notably, decreasing blood Phe levels through dietary treatment reduced SWD activity under baseline conditions, though it only partly prevented the elevated SWD expression during sleep deprivation. In conclusion, this study in the PAHenu2 mouse model demonstrates that extremely high Phe levels can lead to abnormal brain activity including the development of SWDs. Moreover, the findings suggest that SWD expression can be reduced through dietary restriction of Phe.
Common Questions
What is Phenylketonuria?
Phenylketonuria is a genetic condition where the body cannot properly break down an amino acid called phenylalanine. Without management, it can cause brain damage. It is detected at birth through newborn screening, and a specialised low-phenylalanine diet is the main treatment.
How many clinical trials are available for Phenylketonuria?
RareWays currently indexes 154 clinical trials for Phenylketonuria, of which 25 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Phenylketonuria come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Phenylketonuria.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.